A citation-based method for searching scientific literature

Hongtao Yu, Weifeng Tang, Peter J Greasley, Robert C Penland, David W Boulton, K Melissa Hallow. J Clin Pharmacol 2021
Times Cited: 3







List of co-cited articles
2 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes.
Stephen D Wiviott, Itamar Raz, Marc P Bonaca, Ofri Mosenzon, Eri T Kato, Avivit Cahn, Michael G Silverman, Thomas A Zelniker, Julia F Kuder, Sabina A Murphy,[...]. N Engl J Med 2019
66

Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction.
John J V McMurray, Scott D Solomon, Silvio E Inzucchi, Lars Køber, Mikhail N Kosiborod, Felipe A Martinez, Piotr Ponikowski, Marc S Sabatine, Inder S Anand, Jan Bělohlávek,[...]. N Engl J Med 2019
66

Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study.
D Levy, R J Garrison, D D Savage, W B Kannel, W P Castelli. N Engl J Med 1990
33


Deletion of Fn14 receptor protects from right heart fibrosis and dysfunction.
Tatyana Novoyatleva, Yves Schymura, Wiebke Janssen, Frederic Strobl, Jakub M Swiercz, Chinmoy Patra, Guido Posern, Astrid Wietelmann, Timothy S Zheng, Ralph T Schermuly,[...]. Basic Res Cardiol 2013
55
33

Empagliflozin Prevents Worsening of Cardiac Function in an Experimental Model of Pressure Overload-Induced Heart Failure.
Nikole J Byrne, Nirmal Parajuli, Jody L Levasseur, Jamie Boisvenue, Donna L Beker, Grant Masson, Paul W M Fedak, Subodh Verma, Jason R B Dyck. JACC Basic Transl Sci 2017
81
33

A Simplified, Langendorff-Free Method for Concomitant Isolation of Viable Cardiac Myocytes and Nonmyocytes From the Adult Mouse Heart.
Matthew Ackers-Johnson, Peter Yiqing Li, Andrew P Holmes, Sian-Marie O'Brien, Davor Pavlovic, Roger S Foo. Circ Res 2016
162
33

Amelioration of diastolic dysfunction by dapagliflozin in a non-diabetic model involves coronary endothelium.
Donato Cappetta, Antonella De Angelis, Loreta Pia Ciuffreda, Raffaele Coppini, Anna Cozzolino, Agostino Miccichè, Carmela Dell'Aversana, Domenico D'Amario, Eleonora Cianflone, Cristina Scavone,[...]. Pharmacol Res 2020
21
33

Shift to Fatty Substrate Utilization in Response to Sodium-Glucose Cotransporter 2 Inhibition in Subjects Without Diabetes and Patients With Type 2 Diabetes.
Ele Ferrannini, Simona Baldi, Silvia Frascerra, Brenno Astiarraga, Tim Heise, Roberto Bizzotto, Andrea Mari, Thomas R Pieber, Elza Muscelli. Diabetes 2016
283
33

The NF-κB subunit c-Rel stimulates cardiac hypertrophy and fibrosis.
Silvia Gaspar-Pereira, Nicola Fullard, Paul A Townsend, Paul S Banks, Elizabeth L Ellis, Christopher Fox, Aidan G Maxwell, Lindsay B Murphy, Adam Kirk, Ralf Bauer,[...]. Am J Pathol 2012
55
33

Hydrochlorothiazide vs chlorthalidone, indapamide, and potassium-sparing/hydrochlorothiazide diuretics for reducing left ventricular hypertrophy: A systematic review and meta-analysis.
George C Roush, Ramy Abdelfattah, Steven Song, Michael E Ernst, Domenic A Sica, John B Kostis. J Clin Hypertens (Greenwich) 2018
9
33


Functional, structural and molecular aspects of diastolic heart failure in the diabetic (mRen-2)27 rat.
K A Connelly, D J Kelly, Y Zhang, D L Prior, J Martin, A J Cox, K Thai, M P Feneley, J Tsoporis, K E White,[...]. Cardiovasc Res 2007
68
33

The role of the Grb2-p38 MAPK signaling pathway in cardiac hypertrophy and fibrosis.
Shaosong Zhang, Carla Weinheimer, Michael Courtois, Attila Kovacs, Cindy E Zhang, Alec M Cheng, Yibin Wang, Anthony J Muslin. J Clin Invest 2003
156
33

Myocardial cell death in human diabetes.
A Frustaci, J Kajstura, C Chimenti, I Jakoniuk, A Leri, A Maseri, B Nadal-Ginard, P Anversa. Circ Res 2000
593
33

Activation of NF-kappa B is required for hypertrophic growth of primary rat neonatal ventricular cardiomyocytes.
N H Purcell, G Tang, C Yu, F Mercurio, J A DiDonato, A Lin. Proc Natl Acad Sci U S A 2001
276
33

TWEAK/Fn14 interaction regulates RANTES production, BMP-2-induced differentiation, and RANKL expression in mouse osteoblastic MC3T3-E1 cells.
Takashi Ando, Jiro Ichikawa, Masanori Wako, Kyosuke Hatsushika, Yoshiyuki Watanabe, Michitomo Sakuma, Kachio Tasaka, Hideoki Ogawa, Yoshiki Hamada, Hideo Yagita,[...]. Arthritis Res Ther 2006
55
33

Left ventricular hypertrophy and antihypertensive therapy.
F H Messerli, S Oren, E Grossman. Drugs 1988
43
33

The Fn14 cytoplasmic tail binds tumour-necrosis-factor-receptor-associated factors 1, 2, 3 and 5 and mediates nuclear factor-kappaB activation.
Sharron A N Brown, Christine M Richards, Heather N Hanscom, Sheau-Line Y Feng, Jeffrey A Winkles. Biochem J 2003
152
33

Sirtuin 1 activation attenuates cardiac fibrosis in a rodent pressure overload model by modifying Smad2/3 transactivation.
Antoinette Bugyei-Twum, Christopher Ford, Robert Civitarese, Jessica Seegobin, Suzanne L Advani, Jean-Francois Desjardins, Golam Kabir, Yanling Zhang, Melissa Mitchell, Jennifer Switzer,[...]. Cardiovasc Res 2018
35
33

Tissue Doppler imaging differentiates physiological from pathological pressure-overload left ventricular hypertrophy in rats.
Geneviève Derumeaux, Paul Mulder, Vincent Richard, Abdeslam Chagraoui, Catherine Nafeh, Fabrice Bauer, Jean-Paul Henry, Christian Thuillez. Circulation 2002
121
33

Sodium-glucose co-transporter 2 inhibition with empagliflozin improves cardiac function in non-diabetic rats with left ventricular dysfunction after myocardial infarction.
Salva R Yurista, Herman H W Silljé, Silke U Oberdorf-Maass, Elisabeth-Maria Schouten, Mario G Pavez Giani, Jan-Luuk Hillebrands, Harry van Goor, Dirk J van Veldhuisen, Rudolf A de Boer, B Daan Westenbrink. Eur J Heart Fail 2019
102
33

Novel metabolic risk factors for incident heart failure and their relationship with obesity: the MESA (Multi-Ethnic Study of Atherosclerosis) study.
Hossein Bahrami, David A Bluemke, Richard Kronmal, Alain G Bertoni, Donald M Lloyd-Jones, Eyal Shahar, Moyses Szklo, João A C Lima. J Am Coll Cardiol 2008
241
33

A novel role for tumor necrosis factor-like weak inducer of apoptosis (TWEAK) in the development of cardiac dysfunction and failure.
Mohit Jain, Aniela Jakubowski, Lei Cui, Jianru Shi, Lihe Su, Michael Bauer, Jian Guan, Chee Chew Lim, Yoshiro Naito, Jeffrey S Thompson,[...]. Circulation 2009
81
33

Fibroblast growth factor-inducible 14 mediates macrophage infiltration in heart to promote pressure overload-induced cardiac dysfunction.
Sathya D Unudurthi, Drew M Nassal, Nehal J Patel, Evelyn Thomas, Jane Yu, Curtis G Pierson, Shyam S Bansal, Peter J Mohler, Thomas J Hund. Life Sci 2020
10
33

SGLT2 inhibitor empagliflozin reduces renal growth and albuminuria in proportion to hyperglycemia and prevents glomerular hyperfiltration in diabetic Akita mice.
Volker Vallon, Maria Gerasimova, Michael A Rose, Takahiro Masuda, Joseph Satriano, Eric Mayoux, Hermann Koepsell, Scott C Thomson, Timo Rieg. Am J Physiol Renal Physiol 2014
266
33

TWEAK/Fn14 axis is a positive regulator of cardiac hypertrophy.
Tatyana Novoyatleva, Wiebke Janssen, Astrid Wietelmann, Ralph T Schermuly, Felix B Engel. Cytokine 2013
25
33

Empagliflozin decreases myocardial cytoplasmic Na+ through inhibition of the cardiac Na+/H+ exchanger in rats and rabbits.
Antonius Baartscheer, Cees A Schumacher, Rob C I Wüst, Jan W T Fiolet, Ger J M Stienen, Ruben Coronel, Coert J Zuurbier. Diabetologia 2017
263
33

TWEAK-Fn14 Cytokine-Receptor Axis: A New Player of Myocardial Remodeling and Cardiac Failure.
Tatyana Novoyatleva, Amna Sajjad, Felix B Engel. Front Immunol 2014
28
33

RNAscope: a novel in situ RNA analysis platform for formalin-fixed, paraffin-embedded tissues.
Fay Wang, John Flanagan, Nan Su, Li-Chong Wang, Son Bui, Allissa Nielson, Xingyong Wu, Hong-Thuy Vo, Xiao-Jun Ma, Yuling Luo. J Mol Diagn 2012
33


Dapagliflozin improves left ventricular remodeling and aorta sympathetic tone in a pig model of heart failure with preserved ejection fraction.
Nannan Zhang, Bin Feng, Xuexing Ma, Kangyun Sun, Guidong Xu, Yafeng Zhou. Cardiovasc Diabetol 2019
28
33

FN14 Signaling Plays a Pathogenic Role in a Mouse Model of Experimental Autoimmune Myocarditis.
Andrea Fischer, Mariella Bockstahler, Anna-Maria Müller, Vera Stroikova, Christoph Leib, Gabriele Pfitzer, Hugo A Katus, Ziya Kaya. J Card Fail 2019
2
50



FGF-inducible 14-kDa protein (Fn14) is regulated via the RhoA/ROCK kinase pathway in cardiomyocytes and mediates nuclear factor-kappaB activation by TWEAK.
Emmanuel Chorianopoulos, Thomas Heger, Matthias Lutz, Derk Frank, Florian Bea, Hugo A Katus, Norbert Frey. Basic Res Cardiol 2010
86
33



Empagliflozin improves left ventricular diastolic function of db/db mice.
Julia Moellmann, Barbara M Klinkhammer, Patrick Droste, Ben Kappel, Elias Haj-Yehia, Sebastian Maxeiner, Anna Artati, Jerzy Adamski, Peter Boor, Katharina Schütt,[...]. Biochim Biophys Acta Mol Basis Dis 2020
13
33

Tumour necrosis factor-like weak inducer of apoptosis (TWEAK) and its receptor Fn14 during cardiac remodelling in rats.
E Mustonen, H Säkkinen, H Tokola, E Isopoussu, J Aro, H Leskinen, H Ruskoaho, J Rysä. Acta Physiol (Oxf) 2010
35
33

Off-target effects of sodium-glucose co-transporter 2 blockers: empagliflozin does not inhibit Na+/H+ exchanger-1 or lower [Na+]i in the heart.
Yu Jin Chung, Kyung Chan Park, Sergiy Tokar, Thomas R Eykyn, William Fuller, Davor Pavlovic, Pawel Swietach, Michael J Shattock. Cardiovasc Res 2021
21
33

eNOS deficiency predisposes podocytes to injury in diabetes.
Darren A Yuen, Bailey E Stead, Yanling Zhang, Kathryn E White, M Golam Kabir, Kerri Thai, Suzanne L Advani, Kim A Connelly, Tomoko Takano, Lei Zhu,[...]. J Am Soc Nephrol 2012
101
33


Load-independent effects of empagliflozin contribute to improved cardiac function in experimental heart failure with reduced ejection fraction.
Kim A Connelly, Yanling Zhang, Jean-François Desjardins, Linda Nghiem, Aylin Visram, Sri N Batchu, Verra G Yerra, Golam Kabir, Kerri Thai, Andrew Advani,[...]. Cardiovasc Diabetol 2020
15
33

Load-Dependent Changes in Left Ventricular Structure and Function in a Pathophysiologically Relevant Murine Model of Reversible Heart Failure.
Carla J Weinheimer, Attila Kovacs, Sarah Evans, Scot J Matkovich, Philip M Barger, Douglas L Mann. Circ Heart Fail 2018
21
33

Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure.
Milton Packer, Stefan D Anker, Javed Butler, Gerasimos Filippatos, Stuart J Pocock, Peter Carson, James Januzzi, Subodh Verma, Hiroyuki Tsutsui, Martina Brueckmann,[...]. N Engl J Med 2020
736
33

Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes.
Bruce Neal, Vlado Perkovic, Kenneth W Mahaffey, Dick de Zeeuw, Greg Fulcher, Ngozi Erondu, Wayne Shaw, Gordon Law, Mehul Desai, David R Matthews. N Engl J Med 2017
33

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.
Bernard Zinman, Christoph Wanner, John M Lachin, David Fitchett, Erich Bluhmki, Stefan Hantel, Michaela Mattheus, Theresa Devins, Odd Erik Johansen, Hans J Woerle,[...]. N Engl J Med 2015
33

Dapagliflozin Attenuates Cardiac Remodeling in Mice Model of Cardiac Pressure Overload.
Lin Shi, Diqi Zhu, Shoubao Wang, Aixia Jiang, Fen Li. Am J Hypertens 2019
21
33

SGLT2 mediates glucose reabsorption in the early proximal tubule.
Volker Vallon, Kenneth A Platt, Robyn Cunard, Jana Schroth, Jean Whaley, Scott C Thomson, Hermann Koepsell, Timo Rieg. J Am Soc Nephrol 2011
300
33


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.